3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1/2
2
Phase 1
1
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
1
Conditions
Recurrence
2
Lymphoma, B-Cell
1
Interventions
Dexamethasone
33
Cyclophosphamide
31
fludarabine
19
venetoclax
18
Lenalidomide
16
Bortezomib
16
Cytarabine
13
pembrolizumab
12
Calcium Dobesilate
12
Carboplatin
11
fludarabine phosphate
10
Rituximab
10
pomalidomide
9
Gemcitabine
9
Nivolumab
8
Azacitidine
7
daratumumab
6
carfilzomib
6
blinatumomab
6
Decitabine
6
Bendamustine Hydrochloride
6
selinexor
5
obinutuzumab
5
ibrutinib
5
Vincristine
5
Temozolomide
5
Methotrexate
5
Etoposide
5
Cisplatin
5
tafasitamab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 1/2
×
Recurrence
×
brexucabtagene autoleucel
×
Clear all
NCT02625480
2026-04-09
ZUMA-4
Gilead Sciences
Phase 1/2
Completed
95 enrolled
NCT02614066
2024-11-19
ZUMA-3
Gilead Sciences
Phase 1/2
Completed
125 enrolled
27 charts
1 FDA